Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Trial Profile

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Triamcinolone (Primary) ; Aflibercept
  • Indications Diabetes mellitus; Diabetic macular oedema
  • Focus Adverse reactions
  • Acronyms HULK
  • Sponsors Clearside Biomedical
  • Most Recent Events

    • 09 Aug 2017 Clearside expects to report preliminary results from the this trial by the end of 2017 according to a company media release.
    • 27 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jul 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top